JP2021519753A5 - - Google Patents
Info
- Publication number
- JP2021519753A5 JP2021519753A5 JP2020552191A JP2020552191A JP2021519753A5 JP 2021519753 A5 JP2021519753 A5 JP 2021519753A5 JP 2020552191 A JP2020552191 A JP 2020552191A JP 2020552191 A JP2020552191 A JP 2020552191A JP 2021519753 A5 JP2021519753 A5 JP 2021519753A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- dystrophy
- composition according
- amino
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650004P | 2018-03-29 | 2018-03-29 | |
| US62/650,004 | 2018-03-29 | ||
| PCT/US2019/024726 WO2019191525A1 (en) | 2018-03-29 | 2019-03-29 | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519753A JP2021519753A (ja) | 2021-08-12 |
| JP2021519753A5 true JP2021519753A5 (https=) | 2022-04-01 |
Family
ID=68056529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020552191A Pending JP2021519753A (ja) | 2018-03-29 | 2019-03-29 | 眼障害の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190298674A1 (https=) |
| EP (1) | EP3758693A4 (https=) |
| JP (1) | JP2021519753A (https=) |
| KR (1) | KR20210009306A (https=) |
| CN (1) | CN112218628A (https=) |
| AU (1) | AU2019243586A1 (https=) |
| CA (1) | CA3095468A1 (https=) |
| IL (1) | IL277599A (https=) |
| MX (1) | MX2020010302A (https=) |
| WO (1) | WO2019191525A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR202021080A2 (tr) * | 2020-12-21 | 2022-07-21 | Marmara Ueniversitesi | Thi̇el-behnke kornea di̇strofi̇si̇ (tbkd) i̇çi̇n bi̇r yöntem ve söz konusu yöntem i̇le üreti̇len bi̇r yapay doku i̇skelesi̇ |
| EP4482478A4 (en) * | 2022-02-27 | 2026-03-04 | Univ Northwestern | (3S,4R)-3-AMINO-4-(DIFLUOROMETHYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS USED AS SELECTIVE ORNITHIN AMINOTRANSFERASE ACTIVATORS |
| KR20250034134A (ko) * | 2022-07-06 | 2025-03-10 | 오비드 테라퓨틱스 인크. | 암 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸렌일)사이클로펜트-1-엔-1-카르복실산의 사용 |
| US20240285565A1 (en) * | 2023-02-17 | 2024-08-29 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes |
| JP2026506097A (ja) * | 2023-02-17 | 2026-02-20 | オービッド・セラピューティクス・インコーポレイテッド | 多発性硬化症の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペント－１－エン－１－カルボン酸の使用 |
| US20240285563A1 (en) * | 2023-02-17 | 2024-08-29 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) * | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| CA2790820A1 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| EP2806867A4 (en) * | 2012-01-27 | 2015-09-02 | Catalyst Pharmaceutical Partners Inc | METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS |
| ES2882126T3 (es) * | 2014-11-07 | 2021-12-01 | Univ Northwestern | Inhibición de ornitina aminotransferasa con análogos de GABA para el tratamiento de carcinoma hepatocelular |
| JP6841821B2 (ja) * | 2015-10-09 | 2021-03-10 | ノースウェスタン ユニバーシティ | てんかん、嗜癖および肝細胞癌の処置のためのｇａｂａアミノトランスフェラーゼ不活性化剤としての（ｓ）−３−アミノ−４−（ジフルオロメチレニル）シクロペント−１−エン−１−カルボン酸および関連化合物 |
| US10632088B2 (en) * | 2016-10-10 | 2020-04-28 | Northwestern University | Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria |
| EP4692048A3 (en) * | 2017-02-08 | 2026-04-01 | Ovid Therapeutics Inc. | Methods of treating cdkl5 disorders with the compound ov329 |
| KR20250167147A (ko) * | 2018-02-08 | 2025-11-28 | 오비드 테라퓨틱스 인크. | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
| MX2020012691A (es) * | 2018-05-25 | 2021-02-15 | Univ Northwestern | Proceso para la sintesis del acido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxilico. |
-
2019
- 2019-03-29 JP JP2020552191A patent/JP2021519753A/ja active Pending
- 2019-03-29 CA CA3095468A patent/CA3095468A1/en active Pending
- 2019-03-29 KR KR1020207031345A patent/KR20210009306A/ko not_active Withdrawn
- 2019-03-29 EP EP19777219.7A patent/EP3758693A4/en not_active Withdrawn
- 2019-03-29 US US16/368,907 patent/US20190298674A1/en not_active Abandoned
- 2019-03-29 AU AU2019243586A patent/AU2019243586A1/en not_active Abandoned
- 2019-03-29 MX MX2020010302A patent/MX2020010302A/es unknown
- 2019-03-29 CN CN201980033569.9A patent/CN112218628A/zh active Pending
- 2019-03-29 WO PCT/US2019/024726 patent/WO2019191525A1/en not_active Ceased
-
2020
- 2020-09-24 IL IL277599A patent/IL277599A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519753A5 (https=) | ||
| JP2022548071A5 (https=) | ||
| JP2019524826A5 (https=) | ||
| WO2019191525A1 (en) | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders | |
| Wang et al. | Angle closure glaucoma in congenital ectropion uvea | |
| Choi et al. | Goniotomy for steroid-induced glaucoma: clinical and tonographic evidence to support therapeutic goniotomy | |
| JP2021534217A5 (https=) | ||
| FI3720428T3 (fi) | Dobesiliinihappoa käsittävä oftalminen paikalliskoostumus silmän takasegmentin sairauksien hoitoon | |
| JP2021505554A5 (https=) | ||
| Scuderi et al. | Retinal involvement in pigment dispersion syndrome | |
| IL303513A (en) | Compounds for the treatment of eye diseases | |
| US20220106326A1 (en) | Crystalline forms of therapeutic compounds and uses thereof | |
| Gagliardi et al. | Two cases of therapeutic scleral lenses for KID syndrome | |
| Vijayakumar et al. | Embryology and Pathophysiology of Childhood Glaucoma | |
| US11021487B2 (en) | Crystalline forms of therapeutic compounds and uses thereof | |
| Cherny et al. | Contact Lens Modifications for Boston Keratoprosthesis: Novel Case Report and Review of the Literature | |
| Della Lena et al. | Bilateral Preserflo MicroShunt Implantation after Descemet\'s Stripping Automated Endothelial Keratoplasty: A Case Report | |
| KR102866612B1 (ko) | 셀라폴린 a-1을 포함하는 황반변성, 신생혈관성 안질환, 또는 안구 내 섬유증의 예방 또는 치료용 조성물 | |
| TW202027733A (zh) | 含有葉黃素之點眼液組合物 | |
| Zahid et al. | C1QTNF5 | |
| Koksaldi et al. | Secondary Glaucoma Due to Congenital Ectropion Uveae | |
| Devi et al. | Iridocorneal Endothelial Syndrome: A Case Report | |
| Kozomara et al. | Simultaneous bilateral implantation of ex-press glaucoma shunt for secondary glaucoma treatment due to axenfeld-rieger syndrome: a case report | |
| Nischal | Anterior segment developmental anomalies including aniridia | |
| MEŞEN et al. | Iridocorneal Dysgenesis in Pediatric Population and |